A trial to study efficacy and safety of initial combination therapy with gemigliptin and metformin vs. gemigliptin or metformin monotherapy in drug-naïve patients with type 2 diabetes

Trial Profile

A trial to study efficacy and safety of initial combination therapy with gemigliptin and metformin vs. gemigliptin or metformin monotherapy in drug-naïve patients with type 2 diabetes

Completed
Phase of Trial: Phase III

Latest Information Update: 02 Jun 2016

At a glance

  • Drugs Gemigliptin/metformin (Primary)
  • Indications Type 2 diabetes mellitus
  • Focus Therapeutic Use
  • Most Recent Events

    • 02 Jun 2016 Primary endpoint (change from baseline in HbA1c after 24 weeks) has been met, according to results presented at The 98th Annual Meeting of the Endocrine Society
    • 02 Jun 2016 New trial record
    • 04 Apr 2016 Results presented at The 98th Annual Meeting of the Endocrine Society
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top